Journal article · 2010
What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development.
Journal of Clinical Oncology, 28(15_suppl), 9093 · Published 20 May 2010 · DOI 10.1200/jco.2010.28.15_suppl.9093
In brief
“What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development.” is a 2010 journal article by Haralambos Raftopoulos and 5 co-authors, published in Journal of Clinical Oncology. OpenAlex counts 2 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 2
- Most cited in
- 2015 (1)
- Authors
- 6
Abstract
9093 Background: Patient (pt) involvement in establishing content validity (CV) is critical for QL and PRO instrument development. Instruments usually contain both multidimensional summative items and single Sx items. As endpoints in drug development, the FDA has emphasized Sx assessment in PRO guidance and has questioned the CV of many instruments as not having sufficient… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Raftopoulos, H., Gralla, R. J., Hollen, P. J., Davis, B. J., Petersen, J. A., & Horigan, J. L. (2010). What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development. Journal of Clinical Oncology, 28(15_suppl), 9093. https://doi.org/10.1200/jco.2010.28.15_suppl.9093
MLA 9
Raftopoulos, Haralambos, et al. “What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, 2010, p. 9093. https://doi.org/10.1200/jco.2010.28.15_suppl.9093.
Chicago
Raftopoulos, Haralambos, Richard J. Gralla, Patricia J. Hollen, B. J. Davis, Judith A. Petersen, and J. L. Horigan. 2010. “What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development.” Journal of Clinical Oncology 28 (15_suppl): 9093. https://doi.org/10.1200/jco.2010.28.15_suppl.9093.
Harvard
Raftopoulos, H. et al. (2010) ‘What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development.’, Journal of Clinical Oncology, 28(15_suppl), p. 9093. doi:10.1200/jco.2010.28.15_suppl.9093.
IEEE
H. Raftopoulos, R. J. Gralla, P. J. Hollen, B. J. Davis, J. A. Petersen, and J. L. Horigan, “What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development.,” Journal of Clinical Oncology, vol. 28, no. 15_suppl, p. 9093, 2010, doi: 10.1200/jco.2010.28.15_suppl.9093.
BibTeX
@article{raftopoulos2010what,
title = {{What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development.}},
author = {Raftopoulos, Haralambos and Gralla, Richard J. and Hollen, Patricia J. and Davis, B. J. and Petersen, Judith A. and Horigan, J. L.},
journal = {Journal of Clinical Oncology},
year = {2010},
volume = {28},
number = {15_suppl},
pages = {9093},
doi = {10.1200/jco.2010.28.15_suppl.9093},
url = {https://doi.org/10.1200/jco.2010.28.15_suppl.9093}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer survivorship and care
- patient priorities
- quality of life
- patient-reported outcomes
- content validity
- symptom assessment
- lung cancer
- breast cancer
- prostate cancer
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Raftopoulos, H., Gralla, R. J., Hollen, P. J., Davis, B. J., Petersen, J. A., & Horigan, J. L. (2010). What do patients rank as more important in quality-of-life (QL) and patient-reported outcome (PRO) evaluation: Symptoms (Sx) or summative assessments? Results of a 3,860-patient survey in lung, breast, and prostate cancers with implications for drug development. Journal of Clinical Oncology, 28(15_suppl), 9093. https://doi.org/10.1200/jco.2010.28.15_suppl.9093
How many times has this paper been cited?
2 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Haralambos Raftopoulos, Richard J. Gralla, Patricia J. Hollen, B. J. Davis, Judith A. Petersen, J. L. Horigan.
What is the DOI of this paper?
10.1200/jco.2010.28.15_suppl.9093, permanently at https://doi.org/10.1200/jco.2010.28.15_suppl.9093. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.